BS_ZV68CES9
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 20.07227332457293
- age_years
- 5.564
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.507
- G2M_CHECKPOINT+0.444
- MYC_TARGETS_V1+0.371
- SPERMATOGENESIS+0.261
- PANCREAS_BETA_CELLS+0.247
- DNA_REPAIR+0.173
- MYC_TARGETS_V2+0.151
- PROTEIN_SECRETION+0.149
- UNFOLDED_PROTEIN_RESPONSE+0.093
- MITOTIC_SPINDLE+0.053
Top 10 suppressed
- NOTCH_SIGNALING-0.583
- INTERFERON_ALPHA_RESPONSE-0.554
- INTERFERON_GAMMA_RESPONSE-0.523
- TNFA_SIGNALING_VIA_NFKB-0.476
- INFLAMMATORY_RESPONSE-0.461
- CHOLESTEROL_HOMEOSTASIS-0.417
- IL6_JAK_STAT3_SIGNALING-0.406
- HEDGEHOG_SIGNALING-0.384
- ALLOGRAFT_REJECTION-0.381
- APICAL_SURFACE-0.356
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_KYF0Q0E7 | medulloblastoma | — | 0.959 |
| 2 | BS_9NJHQE9F | medulloblastoma | — | 0.957 |
| 3 | BS_HF3RNN2T | medulloblastoma | — | 0.951 |
| 4 | BS_9M5XJ10G | medulloblastoma | — | 0.949 |
| 5 | BS_H4B5Y6S0 | medulloblastoma | — | 0.949 |
| 6 | BS_SKGJ5SY9 | medulloblastoma | — | 0.949 |
| 7 | BS_EFE4YEK3 | medulloblastoma | — | 0.948 |
| 8 | BS_JFB984RG | medulloblastoma | — | 0.947 |
| 9 | BS_4CP4T22V | medulloblastoma | — | 0.945 |
| 10 | BS_Z7PKVY9J | medulloblastoma | — | 0.943 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.507 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.444 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.371 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.261 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.247 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.173 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.151 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.149 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.093 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.053 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.005 | Inavolisib | — uncovered |
| PEROXISOME | 0.003 | Idelalisib | — uncovered |